Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
AIDS and Behavior
Published in: AIDS and Behavior 11/2016

01-11-2016 | Original Paper

Substance Use and Adherence Among People Living with HIV/AIDS Receiving cART in Latin America

Authors: Raquel B. De Boni, Bryan E. Shepherd, Beatriz Grinsztejn, Carina Cesar, Claudia Cortés, Denis Padgett, Eduardo Gotuzzo, Pablo F. Belaunzarán-Zamudio, Peter F. Rebeiro, Stephany N. Duda, Catherine C. McGowan

Published in: AIDS and Behavior | Issue 11/2016

Login to get access

Abstract

This cross-sectional study describes substance use prevalence and its association with combination antiretroviral therapy (cART) adherence among 3343 individuals receiving care at HIV clinics in Argentina, Brazil, Chile, Honduras, Mexico, and Peru. A rapid screening tool evaluated self-reported 7-day recall of alcohol, marijuana, cocaine, heroin, and methamphetamine use, and missed cART doses. Overall, 29.3 % individuals reported having ≥1 alcoholic drinks, 5.0 % reported any illicit drug use and 17.0 % reported missed cART doses. In the logistic regression model, compared to no substance use, alcohol use [adjusted odds ratio (AOR) = 2.46, 95 % confidence interval (CI): 1.99–3.05], illicit drug use (AOR = 3.57, 95 % CI: 2.02–6.30), and using both alcohol and illicit drugs (AOR = 4.98, 95 % CI: 3.19–7.79) were associated with missed cART doses. The associations between substance use and likelihood of missing cART doses point to the need of targeting alcohol and illicit drug use to improve adherence among people living with HIV in Latin America.
Literature
1.
Degenhardt L, Hall W. Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet. 2012;379(9810):55–70.CrossRefPubMed
2.
Kipp AM, Desruisseau AJ, Qian HZ. Non-injection drug use and HIV disease progression in the era of combination antiretroviral therapy. J Subst Abuse Treat. 2011;40(4):386–96.CrossRefPubMedPubMedCentral
3.
Meyer JP, Althoff AL, Altice FL. Optimizing care for HIV-Infected people who use drugs: evidence-based approaches to overcoming healthcare disparities. Clin Infect Dis. 2013;57(9):1309–17.CrossRefPubMedPubMedCentral
4.
McGowan CC, Weinstein DD, Samenow CP, Stinnette SE, Barkanic G, Rebeiro PF, et al. Drug use and receipt of highly active antiretroviral therapy among HIV-infected persons in two U.S. clinic cohorts. PLoS One. 2011;6(4):1–8.CrossRef
5.
Cohn SE, Jiang H, McCutchan JA, Koletar SL, Murphy RL, Robertson KR, et al. Association of ongoing drug and alcohol use with non-adherence to antiretroviral therapy and higher risk of AIDS and death: results from ACTG 362. AIDS Care. 2011;23(6):775–85.CrossRefPubMedPubMedCentral
6.
Lucas GM. Substance abuse, adherence with antiretroviral therapy, and clinical outcomes among HIV-infected individuals. Life Sci. 2011;88(21–22):948–52.CrossRefPubMed
7.
Arnsten JH, Demas PA, Farzadegan H, Grant RW, Gourevitch N, Chang C, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-reported and electronic monitoring. Clin Infect Dis. 2001;33(8):1417–23.CrossRefPubMedPubMedCentral
8.
Mathers BM, Degenhardt L, Phillips B, Wiessing L, Hickman M, Strathdee SA, Wodak A, Panda S, Tyndall M, Toufik A, Mattick RP, and 2007 Reference Group to the UN on HIV and Injecting Drug Use. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet. 2008;372(9651):1733–45.CrossRefPubMed
9.
Mimiaga MJ, Reisner SL, Grasso C, Crane HM, Safren SA, Kitahata MM. Substance use among HIV-infected patients engaged in primary care in the United States: findings from the Centers for AIDS Research Network of Integrated Clinical Systems Cohort. Am J Public Health. 2013;103(8):1457–67.CrossRefPubMedPubMedCentral
10.
Wakefield JC, Schmitz MF. The harmful dysfunction model of alcohol use disorder: revised criteria to improve the validity of diagnosis and prevalence estimates. Addiction. 2015;110:931–42.CrossRefPubMed
11.
Azar MM, Springer SA, Meyer JP, Altice FL. A systematic review of the impact of alcohol use disorders on HIV treatment outcomes, adherence to antiretroviral therapy and health care utilization. Drug Alcohol Depend. 2010;112(3):178–93.CrossRefPubMedPubMedCentral
12.
Chibanda D, Benjamin L, Weiss HA, Abas M. Mental, neurological, and substance use disorders in people living with HIV/AIDS in low- and middle-income countries. J Acquir Immune Defic Syndr. 2014;67:s54–67.CrossRefPubMed
13.
Gonzalez A, Barinas J, O’Cleirigh C. Substance use: impact on adherence and HIV medical treatment. Curr HIV/AIDS Rep. 2011;8(4):223–34.CrossRefPubMed
14.
Malta M, Magnanini M, Strathdee SA, Bastos FI. Adherence to antiretroviral therapy among HIV-Infected drug users: a meta-analysis. AIDS Behav. 2010;14:731–47.CrossRefPubMed
15.
UNODC. World Drug Report. Vienna: United Nations; 2013.
16.
Teixeira C, Dourado MDL, Santos MP, Brites C. Impact of use of alcohol and illicit drugs by AIDS patients on adherence to antiretroviral therapy in Bahia, Brazil. AIDS Res Hum Retroviruses. 2013;29:799–804.CrossRefPubMed
17.
Ferro E, Weikum D, Vagenas P, Copenhaver M, Gonzales P, Peinado J, et al. Alcohol use disorders negatively influence antiretroviral medication adherence among men who have sex with men in Peru. AIDS Care. 2015;27(1):93–104.CrossRefPubMed
18.
Mcgowan CC, Cahn P, Gotuzzo E, Padgett D, Pape JW, Wolff M, et al. Cohort profile: Caribbean, Central and South America Network for HIV research (CCASAnet) collaboration within the International Epidemiologic Databases to Evaluate AIDS (IeDEA) programme. Int J Epidemiol. 2007;36:969–76.CrossRefPubMed
19.
Rasbach DA, Desruisseau AJ, Kipp AM, Stinnette S, Kheshti A, Shepherd BE, et al. Active cocaine use is associated with lack of HIV-1 virologic suppression independent of nonadherence to antiretroviral therapy: use of a rapid screening tool during routine clinic visits. AIDS Care. 2013;25(1):109–17.CrossRefPubMed
20.
21.
Macdonald S, Pakula B, Martin G, Wells S, Borges G, Roth E, et al. Health profiles of clients in substance abuse treatment: a comparison of clients dependent on alcohol or cocaine with those concurrently dependent. Subst Use Misuse. 2014;49(14):1899–907.CrossRefPubMed
22.
Cofrancesco J, Scherzer R, Tien P, Gibert C, Southwell H, Sidney S, et al. Illicit drug use and HIV treatment outcomes in a US cohort. AIDS. 2008;22(3):357–65.CrossRefPubMedPubMedCentral
23.
24.
25.
Abdalla RR, Madruga CS, Ribeiro M, Pinsky I, Caetano R, Laranjeira R. Prevalence of cocaine use in Brazil: data from the II Brazilian National Alcohol and Drugs Survey (BNADS). Addict Behav. 2014;39(1):297–301.CrossRefPubMed
26.
SantosCruz M, Andrade T, Bastos FI, Leal E, Bertoni N, Villar LM, et al. Key drug use, health and socio-economic characteristics of young crack users in two Brazilian cities. Int J Drug Policy. 2013;24(5):432–8.CrossRef
27.
Edlin R, Irwin K, Faruque S, McCoy C, Word C, Serrano Y, et al. Intersecting epidemics—crack cocaine use and HIV infection among inner-city young adults. N Engl J Med. 1994;331(21):1422–7.CrossRefPubMed
28.
Bell C, Metsch L, Vogenthaler N, Cardenas G, Rodriguez A, Locascio V, et al. Never in care: characteristics of HIV-infected crack cocaine users in two US cities who never been to outpatient HIV care. J Acquir Immune Defic Syndr. 2010;54(4):376–80.CrossRefPubMedPubMedCentral
29.
Metsch LR, Pereyra M, Brewer TH. Use of HIV health care in HIV-seropositive crack cocaine smokers and other active drug users. J Subst Abuse. 2001;13(1–2):155–67.CrossRefPubMed
30.
Rentsch C, Tate JP, Akgün KM, Crystal S, Wang KH, Ryan Greysen S, et al. Alcohol-related diagnoses and all-cause hospitalization among HIV-infected and uninfected patients: a longitudinal analysis of United States Veterans from 1997 to 2011. AIDS Behav. 2015. doi:10.1007/s10461-015-1025-y.
31.
Elliott JC, Aharonovich E, O’Leary A, Johnston B, Hasin DS. Perceived medical risks of drinking, alcohol consumption, and hepatitis C status among heavily drinking HIV primary care patients. Alcohol Clin Exp Res. 2014;38(12):3052–9.CrossRefPubMedPubMedCentral
32.
Mitchell AJ, Meader N, Bird V, Rizzo M. Clinical recognition and recording of alcohol disorders by clinicians in primary and secondary care: meta-analysis. Br J Psychiatry. 2012;201:93–100.CrossRefPubMed
33.
Lima V, Harrigan R, Bangsberg D, Hogg R, Gross R, Yip B, et al. The combined effect of modern Highly Active Antiretroviral Therapy regimens and adherence on mortality over time. J Acquir Immune Defic Syndr. 2009;50(5):529–36.CrossRefPubMedPubMedCentral
34.
Bangsberg DR, Perry S, Charlebois ED, Clark RA, Roberston M, Zolopa AR, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001;15(9):1181–3.CrossRefPubMed
35.
Ortego C, Huedo-Medina TB, Llorca J, Sevilla L, Santos P, Rodríguez E, et al. Adherence to highly active antiretroviral therapy (HAART): a meta-analysis. AIDS Behav. 2011;15(7):1381–96.CrossRefPubMed
36.
Hugen PWH, Langebeek N, Burger DM, Zomer B, van Leusen R, Schuurman R, et al. Assessment of adherence to HIV protease inhibitors: comparison and combination of various methods, including MEMS (electronic monitoring), patient and nurse report, and therapeutic drug monitoring. J Acquir Immune Defic Syndr. 2002;30(3):324–34.CrossRefPubMed
37.
38.
Barclay TR, Hinkin CH, Castellon SA, Mason KI, Reinhard MJ, Marion SD. Age-associated predictors of medication adherence in HIV-positive adults : health beliefs, self-efficacy, and neurocognitive status. Heal Psychol. 2010;26(1):40–9.CrossRef
39.
Hinkin CH, Hardy DJ, Mason KI, Castellon SA, Durvasula RS, Lam MN, et al. Medication adherence in HIV-infected adults: effect of patient age, cognitive status, and substance abuse. AIDS. 2004;18(Suppl 1):S19–25.CrossRefPubMedPubMedCentral
40.
Ghidei L, Simone M, Salow M, Zimmerman K, Paquin A, Skarf M, et al. Aging, antiretrovirals, and adherence: a meta analysis of adherence among older HIV-infected individuals. Drugs Aging. 2013;30(10):997–1003.CrossRef
41.
Yehia BR, Rebeiro P, Althoff KN, Agwu AL, Horberg MA, Samji H, et al. Impact of age on retention in care and viral suppression. J AIDS. 2015;68(4):413–9.
Metadata
Title
Substance Use and Adherence Among People Living with HIV/AIDS Receiving cART in Latin America
Authors
Raquel B. De Boni
Bryan E. Shepherd
Beatriz Grinsztejn
Carina Cesar
Claudia Cortés
Denis Padgett
Eduardo Gotuzzo
Pablo F. Belaunzarán-Zamudio
Peter F. Rebeiro
Stephany N. Duda
Catherine C. McGowan
Publication date
01-11-2016
Publisher
Springer US
Published in
AIDS and Behavior / Issue 11/2016
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-016-1398-6

Other articles of this Issue 11/2016

AIDS and Behavior 11/2016 Go to the issue

Original Paper

Does Adherence Change When No One is Looking? Comparing Announced and Unannounced Tenofovir Levels in a PrEP Trial

Substantive Review

A Review of HIV Prevention Studies that Use Social Networking Sites: Implications for Recruitment, Health Promotion Campaigns, and Efficacy Trials

Original Paper

Baseline Predictors of High Adherence to a Coitally Dependent Microbicide Gel Based on an Objective Marker of Use: Findings from the Carraguard Phase 3 Trial

Erratum

Erratum to: Sharing of Investigational Drug Among Participants in the Voice Trial

Original Paper

Adherence and Acceptability of a Multidrug Vaginal Ring for HIV Prevention in a Phase I Study in the United States

Original Paper

The Acceptability and Perceived Usefulness of a Weekly Clinical SMS Program to Promote HIV Antiretroviral Medication Adherence in KwaZulu-Natal, South Africa
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits